Press Releases

Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion

Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026

Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis

Press Release: Myqorzo and Redemplo approved in China

Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes

Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

Press release: Availability of the Q4 2025 Aide memoire

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases

Press Release: Sanofi completes acquisition of Vicebio

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria